Intellia: cash behind clinical execution
Intellia reported $628.4M of cash, equivalents and marketable securities at June 30. A proposed $500M year-end hurdle tracks resources without independently validating runway projections.
Intellia Therapeutics / NTLAPublic biotechcash-positionDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- June is a historical baseline; $500M is a proposed hurdle, not guidance. Later financing/spending must be reviewed.
Primary evidence
Reporting date unconfirmed — research candidate
Intellia Q2 2026 results and cash positionCompany source
Potential outcome market
Will Intellia hold more than $500 million of cash, equivalents and marketable securities at December 31, 2026?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.